AVTX
NASDAQAvalo Therapeutics Inc.
Price$19.38+1.25 (+6.93%)
01:30 PM07:45 PM
News · 26 weeks106-36%
2026-01-182026-07-12
Mix6190d
- Insider30(49%)
- Other12(20%)
- SEC Filings12(20%)
- Offering3(5%)
- Analyst2(3%)
- Leadership2(3%)
Latest news
25 items- SECSEC Form S-3 filed by Avalo Therapeutics Inc.S-3 - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics to Participate in the Leerink Partners Therapeutics ForumWAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently rep
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- ANALYSTLeerink Partners initiated coverage on Avalo Therapeutics with a new price targetLeerink Partners initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $38.00
- INSIDERSEC Form 4 filed by Director Philip Ron M4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Jain Rita4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 4,654 shares at a strike of $10.89 and sold $93,080 worth of shares (4,654 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Lind Kevin Robert4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- PRAvalo Therapeutics to Join the Russell 2000® and Russell 3000® IndexesWAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index measures the performance of the largest 3,000 publicly traded U.S. companies, representing approximately 96% of the investable U.S. equity market. The Russell 2000® Index is a subset of the Russell 3000® Index and serves as the leading benchmark for
- INSIDERChief Medical Officer Doyle Mittie exercised 1,450 shares at a strike of $8.04 and sold $26,100 worth of shares (1,450 units at $18.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Philip Ron M4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 3 filed by new insider Philip Ron M3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics Appoints Ron Philip to Board of DirectorsWAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits. "We are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2 LOTUS topline results and transformative fina
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β AntibodyIND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. "Building on the strength of our abdakibart Phase 2 LOTUS topline data and our conviction in the IL-1β pathway, we believe developing a long-acting next-generation molecule is a natural
- INSIDERChief Strategy Officer Riley Jennifer covered exercise/tax liability with 588 shares, decreasing direct ownership by 1% to 39,696 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Legal Officer Varki Paul covered exercise/tax liability with 1,081 shares, decreasing direct ownership by 3% to 32,576 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Financial Officer Sullivan Christopher Ryan covered exercise/tax liability with 138 shares, decreasing direct ownership by 0.34% to 40,773 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie covered exercise/tax liability with 1,084 shares, decreasing direct ownership by 2% to 51,776 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- ANALYSTBofA Securities initiated coverage on Avalo Therapeutics with a new price targetBofA Securities initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $35.00
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- INSIDERSEC Form 4 filed by Director Lind Kevin Robert4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
AVTX FAQ
6 questionsWhere does AVTX stock trade?
Avalo Therapeutics Inc. (AVTX) is listed on NASDAQ.What sector and industry is AVTX in?
Avalo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Avalo Therapeutics Inc. go public?
Avalo Therapeutics Inc. (AVTX) completed its IPO in 2015.What are analysts saying about AVTX?
Avalo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $3800.00 price target on 2026-07-06. Recent price targets range from $2500.00 to $4800.00.What companies are similar to AVTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AVTX side-by-side with any of them on Quantisnow.How can I track AVTX on Quantisnow?
Quantisnow aggregates Avalo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVTX to receive live email and push alerts on every new disclosure.